Last checked at 25 Jan 2022 07:00
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of share options
Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following options ("Options") over a total of 54,282 ordinary shares of 1 pence in the Company have been granted under the Destiny Pharma plc 2020 Long Term Incentive Plan (the "Plan") to the following Directors and PDMR in respect of bonuses due for the financial year ended 31 December 2021:
Name | Position | Options issued Under 2020 LTIP scheme | Total Options held post issue | Percentage of options in the Company held | Ordinary Shares held | Ordinary Shares held as a percentage of issued share capital
|
Neil Clark | Chief Executive Officer | 16,914 | 1,372,534
| 2.29% | 38,462 | 0.06% |
Shaun Claydon | Chief Financial Officer | 11,725 | 863,901 | 1.44% | - | - |
William Love* | Chief Scientific Officer | 11,501 | 1,322,736 | 2.20% | 6,509,500 | 10.87% |
Stephanie Bewick | Chief Business Officer and PDMR | 14,142 | 138,709 | 0.23% | - | - |
*3,317,700 of these Ordinary Shares are held by William Love and 3,191,800 are held by Carole Love
The Options have been granted with a nominal exercise price and will vest on 24 January 2024. The Options were granted under award agreements that incorporated the terms of the Plan.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Manel Mateus / Vici Rabbetts
+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång/Satheesh Nadarajah
+44 (0) 203 705 9330
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-0
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Neil Clark |
2. | Reason for the Notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification/Amendment | Initial notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Destiny Pharma plc |
b) | LEI | 213800O9WH9Z38EHAC95 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
Identification code | DEST GB00BDHSP575 | |
b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 16,914 Ordinary Shares |
d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
e) | Date of the transaction | 24 January 2022 |
f) | Place of the transaction | London Stock Exchange, AIM Market |
1. | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Shaun Claydon |
2. | Reason for the Notification | |
a) | Position/status | Chief Financial Officer |
b) | Initial notification/Amendment | Initial notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Destiny Pharma plc |
b) | LEI | 213800O9WH9Z38EHAC95 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
Identification code | DEST GB00BDHSP575 | |
b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 11,725 Ordinary Shares |
d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
e) | Date of the transaction | 24 January 2022 |
f) | Place of the transaction | London Stock Exchange, AIM Market |
1. | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | William Love |
2. | Reason for the Notification | |
a) | Position/status | Chief Scientific Officer |
b) | Initial notification/Amendment | Initial notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Destiny Pharma plc |
b) | LEI | 213800O9WH9Z38EHAC95 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
Identification code | DEST GB00BDHSP575 | |
b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 11,501 Ordinary Shares |
d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
e) | Date of the transaction | 24 January 2022 |
f) | Place of the transaction | London Stock Exchange, AIM Market |
1. | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Stephanie Bewick |
2. | Reason for the Notification | |
a) | Position/status | Chief Business Officer |
b) | Initial notification/Amendment | Initial notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Destiny Pharma plc |
b) | LEI | 213800O9WH9Z38EHAC95 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
Identification code | DEST GB00BDHSP575 | |
b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 14,142, Ordinary Shares |
d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
e) | Date of the transaction | 24 January 2022 |
f) | Place of the transaction | London Stock Exchange, AIM Market |